Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Comment by dt_coreon Apr 17, 2013 7:52am
171 Views
Post# 21264245

RE: RE: Guesstimating 1Q13 Results

RE: RE: Guesstimating 1Q13 Results

KerBer,

 

Some coments from management on the industry in the AR (recently filed). Would seem to imply that the backdrop has only modestly improved but nothing robust. I suspect these comments might be setting investor expectations for early 2013 results.

 

I'm sticking with my original 1Q13 forecast (I'll guess we'll know in a few weeks, although no date set that I'm aware of). Add to this comments last Q from RH that 1Q13 won't be overly positive or negative and I think it'll be just "ok". Still, it's a step in the right direction.

 

2012 AR

Although conditions (US drought) have eased somewhat in early 2013, the US plains and areas in the west have remained in severe drought conditions.

Bullboard Posts